3月13日 - ** 生物技术公司Corvus Pharmaceuticals CRVS.O股价盘前下跌2%至15.69美元
** 该公司与杰富瑞（Jefferies）扩大了场内股票销售协议，金额上限为2亿美元，将此前2024年设定的1亿美元上限翻倍
** 新协议允许 CRVS 通过多种方式出售股票，包括私人交易和大宗交易，该公司表示。
** CRVS 尚未根据先前的协议出售任何股票；根据一份文件，杰富瑞将从出售的任何股票中获得最多 3% 的佣金。
** 截至上次收盘，股价今年以来上涨了约两倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.